CHINA PHARMA HOLDINGS, INC. 8-K

What Happened

• China Pharma Holdings, Inc. (CPHI) filed an 8-K on Jan 6, 2026 reporting results of its annual meeting held Dec 30, 2025. Holders of 3,501,046 shares (about 69.71% of outstanding common stock as of the Nov 3, 2025 record date) were present or represented, constituting a quorum.
• Stockholders elected three independent directors—Gene Michael Bennett, Yingwen Zhang and Baowen Dong—each receiving the votes noted below. Shareholders also approved an amendment to permit a reverse stock split of up to 1-for-20 (the Board has discretion if and when to implement it) and approved Amendment No.3 to the company’s Amended and Restated 2010 Long-Term Incentive Plan.

Key Details

• Votes for directors: Gene Michael Bennett 3,500,418 for / 628 withheld; Yingwen Zhang 3,500,418 for / 628 withheld; Baowen Dong 3,500,416 for / 630 withheld.
• Reverse split vote: 3,500,256 for / 780 against / 10 abstentions; Board may decide whether and when to effect the reverse split (up to 1-for-20).
• Long-term incentive plan amendment vote: 3,500,258 for / 774 against / 14 abstentions; Amendment No.3 to the 2010 LTIP was approved.

Why It Matters

• The approved reverse split authorization, if implemented, would reduce the number of outstanding shares and increase the per‑share par value proportionally; the Board’s discretion means the change is not immediate but could be used to meet listing standards or change float/marketability.
• Re-election of three independent directors affects board composition and corporate governance going forward.
• Approval of the LTIP amendment signals the company has shareholder support to modify its equity compensation program, which can impact future dilution and executive/employee incentives.